Meeting
2023 ASCO Annual Meeting
Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.
Authors
Rachel Occhiogrosso Abelman
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Rachel Occhiogrosso Abelman , Laura Spring , Geoffrey G. Fell , Phoebe Ryan , Neelima Vidula , Arielle J Medford , Jennifer Shin , Elizabeth Abraham , Seth Andrew Wander , Steven J. Isakoff , Beverly Moy , Leif W. Ellisen , Aditya Bardia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1022)
DOI
10.1200/JCO.2023.41.16_suppl.1022
Abstract #
1022
Poster Bd #
243
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan.
First Author: Nicholas Mai
Poster
2022 ASCO Annual Meeting
Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress).
First Author: Ian E. Krop
Poster
2024 ASCO Annual Meeting
Real world experience of trastuzumab deruxtecan for the treatment of metastatic breast cancer in the UK.
First Author: Andy Cheng
Poster
2024 ASCO Annual Meeting
The design, preclinical study and phase I dose escalation plan of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment.
First Author: Shanshan Jin